Medistem (OTCMKTS:MEDS), Enters Collaboration with Boston Academic Teaching Hospital to Expand Preclinical Data in Type 1 Diabetes

Boston, United States, July 30, 2013 - (ABN Newswire) - Medistem, Inc. (OTCMKTS:MEDS - News), announced today it has entered into collaboration with Reza Abdi, M.D., Transplant Nephrologist at Brigham and Women's Hospital and Assistant Professor of Medicine, Harvard Medical School. Under the collaboration, the Company will provide Dr. Abdi with its Endometrial Regenerative Cells (ERCs) and it is expected that his research would support FDA clearance to initiate clinical trials to use ERCs as a treatment for Type 1 Diabetes. Currently, the Company has FDA clearance to initiate a dose-escalating Phase I clinical trial to use ERCs in patients with critical limb ischemia, a complication of diabetes.

"Currently there are no treatments that reverse Type 1 diabetes. ERCs have a great potential to emerge as a cell therapy for type 1 diabetes by blocking the pathological autoimmune process that is causative of the disease," said Dr. Abdi.

"An independent study conducted by the National Institutes of Health (NIH), has shown that our ERCs posses superior ability to modulate immune response as compared to other types of stem cells," furthermore "In previous studies, ERCs have shown the ability to produce chemical signals that inhibit autoimmune conditions such as Type 1 diabetes and multiple sclerosis." said Alan J. Lewis, Ph.D., Chief Executive Officer of Medistem. "We are delighted to be working with Dr. Abdi as we believe this collaboration could lead to a breakthrough in the treatment of Type 1 Diabetes."

About Medistem Inc.:

Medistem, Inc., is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes.

Contact:

 
Phone: +1-858-352-7071
E-mail: [email protected]
www.medisteminc.com 

Source:

Medistem Inc.

Suggested Articles

Scientists have long known that fatty livers can significantly increase the risk of the organ developing cancer. Now, early research shows why.

Scripps Research scientists found a compound related to resveratrol could lower stem cells' defense for more efficient delivery of gene therapy.

Cancer has always mirrored evolution, but now researchers are developing a new class of drug that blocks the mutations that lead to drug resistance.